Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

HIV-1 Non Group-M Phenotypic Susceptibility to Ibalizumab.

Journal of medical virology - 1 Apr 2026

Poisson Lucie, Hingrat Quentin Le, Lermechain Fanny, Tombette Fabienne, Jullien Henri, Plantier Jean-Christophe, Alessandri-Gradt Elodie

Abstract excerpt

The study assessed the phenotypic susceptibility of non group-M human immunodeficiency virus type 1 (HIV-1/non-M) clinical isolates to ibalizumab, the first-in-class long-acting CD4-directed post-attachment inhibitor. Thirty isolates were tested: 1 HIV-1/M (reference strain BRU.HXB2), 2 HIV-1/N, 26 HIV-1/O and 1 HIV-1/P. A phenotypic in vitro assay was performed by pre-incubating peripheral blood mononuclear...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Viral Load
Share to Anti-HIV Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antibodies, Monoclonal

Share to Glycosylation

Share to HIV Infections

Share to Inhibitory Concentration 50

Share to Leukocytes, Mononuclear

Source

Open in PubMed Open full text

Identifiers

PMID: 41964438
DOI: 10.1002/jmv.70911
PMCID: PMC13069599

Genes

MPI
CD4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

HIV-1 Non Group-M Phenotypic Susceptibility to Ibalizumab.PMID 41964438Read ↗

Loss of Asparagine-Linked Glycosylation Sites in Variable Region 5 of Human Immunodeficiency Virus Type 1 Envelope Is Associated with Resistance to CD4 Antibody IbalizumabSemantic proximity Read ↗

HIV-1 non-group M phenotypic susceptibility to integrase strand transfer inhibitors.Semantic proximity Read ↗

HIV-1 and its resistance to peptidic carbohydrate-binding agents (CBAs): an overview.Semantic proximity Read ↗

In-vitro phenotypic susceptibility of HIV-1 'non-B' integrase inhibitors naive clinical isolates to dolutegravir and raltegravir.Semantic proximity Read ↗

Impact of natural polymorphisms of HIV-1 non-group M on genotypic susceptibility to the attachment inhibitor fostemsavir.Semantic proximity Read ↗

Susceptibility of human immunodeficiency virus type 1 group O isolates to antiretroviral agents: in vitro phenotypic and genotypic analysesSemantic proximity Read ↗

<i>In vitro</i> phenotypic susceptibility of HIV-1 non-group M to CCR5 inhibitor (Maraviroc): TROPI-CO studySemantic proximity Read ↗

Genotypic correlates of susceptibility to HIV-1 attachment inhibitor BMS-626529, the active agent of the prodrug BMS-663068Semantic proximity Read ↗

Resistance of HIV-1 to the broadly HIV-1-neutralizing, anti-carbohydrate antibody 2G12.Semantic proximity Read ↗

In vitro phenotypic susceptibility of HIV-1 non-group M to CCR5 inhibitor (maraviroc): TROPI-CO study.Semantic proximity Read ↗

A genotypic assay for the amplification and sequencing of integrase from diverse HIV-1 group M subtypes.Semantic proximity Read ↗

HIV-1 Group O Genotypes and Phenotypes: Relationship to Fitness and Susceptibility to Antiretroviral Drugs.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.